Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
(Date:2/26/2015)... 26, 2015 The Pittcon 2015 ... the Ernest N. Morial Convention Center in New ... of February 19, 2015) displaying products and services ... and government labs. The Exposition will offer the ... limited to, analytical chemistry; drug discovery; nanotechnology; life ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Innovation ... are emerging from unexpected parts of the world ... From agriculture to manufacturing to health care, ... and environmental realities and socio-political trends shake the ... the key ingredient for CEOs to survive the ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... 4 Biotest Pharmaceuticals,Corporation, a leading developer ... new management team as part of the ... Pharmaceuticals (Nasdaq:,NABI) and the creation of Biotest ... Pharmaceuticals Corporation Completes Acquisition,of Nabi Biologics Business ...
... Dec. 4 Biotest Pharmaceuticals,Corporation, a leading ... it has completed the acquisition of the ... unit for $185 million,in cash. Biotest Pharmaceuticals ... announced the acquisition of the Nabi Biologics ...
... Genetics to Provide Testing for Important Cancer and Leukemia Group ... ... Genzyme Genetics,a business unit of Genzyme Corporation (Nasdaq: GENZ ), ... sponsored by,the National Cancer Institute. The multi-center study will include 1,700,newly diagnosed ...
Cached Biology Technology:Biotest Pharmaceuticals Corporation Announces Management Team 2Biotest Pharmaceuticals Corporation Announces Management Team 3Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit 2Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit 3National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment 2National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment 3National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment 4
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... CA February 4, 2013 A team led by ... cellular events that appear key to lupus, a debilitating autoimmune ... findings suggest that blocking this pathway in lupus-triggering cells could ... new study, described in an online Early Edition of the ...
... of activity at the back of the brain ... would respond to an experimental rapid-acting antidepressant, a ... "We have discovered a potential neuroimaging ... selection by revealing brain-based differences between patients," explained ...
... of American Societies for Experimental Biology (FASEB) announces ... Conference (SRC): TGF-β Superfamily: Signaling in Development and ... Development and Disease" is an important and unique ... family members in developmental and homeostatic processes is ...
Cached Biology News:Scientists find a key element of lupus, suggesting better drug targets 2Scientists find a key element of lupus, suggesting better drug targets 3Scientists find a key element of lupus, suggesting better drug targets 4Imaging biomarker predicts response to rapid antidepressant 2Imaging biomarker predicts response to rapid antidepressant 3